These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25621773)

  • 1. [Sustainability and new anticancer drugs].
    Perrone F
    Recenti Prog Med; 2015 Jan; 106(1):11-3. PubMed ID: 25621773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
    Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dose reassessment: An answer to the high cost of drugs used in oncology?].
    Levêque D
    Bull Cancer; 2019 Sep; 106(9):719-724. PubMed ID: 31202558
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.
    Safonov A; Wang S; Gross CP; Agarwal D; Bianchini G; Pusztai L; Hatzis C
    Breast Cancer Res Treat; 2016 Jan; 155(2):223-34. PubMed ID: 26749360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reality of economics for oncologists.
    Taylor D
    Breast; 2017 Jun; 33():183-190. PubMed ID: 28432979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pfizer to make palbociclib temporarily free on NHS.
    Burki TK
    Lancet Oncol; 2017 Jun; 18(6):e309. PubMed ID: 28506556
    [No Abstract]   [Full Text] [Related]  

  • 7. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 8. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
    Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
    ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
    Raphael J; Helou J; Pritchard KI; Naimark DM
    Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
    Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
    J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
    Lee JA; Bubendorf L; Stahel R; Peters S
    Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer.
    Lu S; Zhang J; Ye M; Wang B; Wu B
    Pharmacogenomics; 2016 Jun; 17(9):985-94. PubMed ID: 27266545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of cancer across the European Union: a population-based cost analysis.
    Luengo-Fernandez R; Leal J; Gray A; Sullivan R
    Lancet Oncol; 2013 Nov; 14(12):1165-74. PubMed ID: 24131614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations in the Care of Non-Small-Cell Lung Cancer: The Value Imperative.
    Kelly R; Houseknecht S
    Oncology (Williston Park); 2018 Nov; 32(11):534-40. PubMed ID: 30474101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
    Guérin A; Sasane M; Zhang J; Culver KW; Dea K; Nitulescu R; Wu EQ
    J Med Econ; 2015 Apr; 18(4):312-22. PubMed ID: 25565443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009.
    Wong NS; Anderson BO; Khoo KS; Ang PT; Yip CH; Lu YS; Voravud N; Shao ZM; Pritchard KI;
    Lancet Oncol; 2009 Nov; 10(11):1077-85. PubMed ID: 19880061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies?
    Chouaid C; Borget I; Vergnenegre A
    J Clin Oncol; 2014 Nov; 32(31):3577. PubMed ID: 25199755
    [No Abstract]   [Full Text] [Related]  

  • 19. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
    Gilbert JA
    Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
    [No Abstract]   [Full Text] [Related]  

  • 20. [Economic evaluation in oncology].
    Schöffski O
    Med Klin (Munich); 2000 Jun; 95 Suppl 1():14-7. PubMed ID: 10941248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.